Literature DB >> 11772328

Management of growth retardation in the young patient with Crohn's disease.

Anne Ballinger1.   

Abstract

Linear growth retardation is a major complication of Crohn's disease that occurs in children. It is related both to undernutrition and to direct effects of the inflammatory process on the growth axis. Enteral nutrition (elemental, semi-elemental or polymeric diet) employed as the sole source of nutrition remains a mainstay of treatment of active Crohn's disease because it corrects nutritional deficits, has anti-inflammatory effects, heals mucosal inflammation and stimulates growth. Conventional corticosteroids have adverse effects on growth and preliminary data suggest that an ileal-release preparation of budesonide may also suppress linear growth. 6-Mercaptopurine (6-MP) and its prodrug azathioprine maintain remission in children with Crohn's disease. These treatments thus have the potential to improve growth velocity and final adult height.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11772328     DOI: 10.1517/14656566.3.1.1

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  2 in total

1.  Use of exclusive enteral nutrition is just as effective as corticosteroids in newly diagnosed pediatric Crohn's disease.

Authors:  Jason Soo; Bushra A Malik; Justine M Turner; Rabin Persad; Eytan Wine; Kerry Siminoski; Hien Q Huynh
Journal:  Dig Dis Sci       Date:  2013-09-12       Impact factor: 3.199

Review 2.  Late consequences of chronic pediatric illness.

Authors:  Susan Turkel; Maryland Pao
Journal:  Psychiatr Clin North Am       Date:  2007-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.